These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 427817)

  • 1. Killing of tumor cells in vitro by macrophages from mice treated with synthetic dehydrodipeptides.
    Schorlemmer HU; Opitz W; Etschenberg E; Bitter-Suermann D; Hadding U
    Cancer Res; 1979 May; 39(5):1847-53. PubMed ID: 427817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
    Schorlemmer HU; Bosslet K; Sedlacek HH
    Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo modulation of macrophage tumoricidal activity: enhanced tumor cell killing by peritoneal macrophages from mice given injections of sodium periodate.
    Weinberg JB
    J Natl Cancer Inst; 1981 Mar; 66(3):529-33. PubMed ID: 6259399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
    Bara S; Lint TF
    J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor.
    Sotomayor EM; Fu YX; Lopez-Cepero M; Herbert L; Jimenez JJ; Albarracin C; Lopez DM
    J Immunol; 1991 Oct; 147(8):2816-23. PubMed ID: 1918995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.
    Jiang H; Stewart CA; Fast DJ; Leu RW
    J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
    Reisser D; Jeannin JF; Martin F
    C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of murine leukemia virus env gene proteins on macrophage-mediated cytotoxicity in vitro.
    Chapes SK; Takemoto LJ
    Life Sci Adv; 1991; 10():9-21. PubMed ID: 11538406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo activation of nude mouse macrophages by human melanoma cells.
    Benomar A; Gerlier D; Doré JF
    J Natl Cancer Inst; 1987 Jul; 79(1):131-6. PubMed ID: 3474441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in antibody-dependent cellular cytotoxicity and activated killing of tumor cells by macrophage cell lines.
    Ralph P; Nakoinz I
    Cancer Res; 1981 Sep; 41(9 Pt 1):3546-50. PubMed ID: 6973392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
    Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
    J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predisposition of [125I]5-iodo-2'-deoxyuridine-labeled normal and neoplastic mouse fibroblasts to lysis by normal macrophages.
    Evans R; Eidlen DM
    J Natl Cancer Inst; 1983 Nov; 71(5):983-9. PubMed ID: 6580500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of tumor cytolytic/cytostatic factor(s) by in vitro cisplatin treated macrophages: enhanced tumoricidal activity by increase in osmotic fragility of target cells.
    Singh SM; Sodhi A; Pai K; Geetha B
    Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):67-73. PubMed ID: 1804054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective tumoricidal capacity of macrophages from P/J mice: characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli.
    Boraschi D; Meltzer MS
    J Immunol; 1980 Aug; 125(2):771-6. PubMed ID: 6993562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supernatants from ethanol-containing macrophage cultures have cytotoxic activity.
    Wickramasinghe SN
    Alcohol Alcohol; 1986; 21(3):263-8. PubMed ID: 3464283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemorrhage induces enhanced Kupffer cell cytotoxicity while decreasing peritoneal or splenic macrophage capacity. Involvement of cell-associated tumor necrosis factor and reactive nitrogen.
    Ayala A; Perrin MM; Wang P; Ertel W; Chaudry IH
    J Immunol; 1991 Dec; 147(12):4147-54. PubMed ID: 1753090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells.
    Fleischmann CM; Fleischmann WR
    J Biol Regul Homeost Agents; 1995; 9(4):139-45. PubMed ID: 8844338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.